中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2010年
1期
52-55
,共4页
周玥%陈建军%鲁忠元%孔维佳
週玥%陳建軍%魯忠元%孔維佳
주모%진건군%로충원%공유가
变应原%小鼠%鼻炎%变应性%常年性
變應原%小鼠%鼻炎%變應性%常年性
변응원%소서%비염%변응성%상년성
Allergens%mice%Rhinitis,allergic,perennial
目的 探讨新生小鼠早期变应原免疫对后期变应性鼻炎(allergic:rhinitis,AR)发生发展的影响.方法 BALB/c新生小鼠24只,按随机数字表法分为4组:小剂量组、大剂量组、阴性对照组、阳性对照组,每组6只.于出生后第1、5、12天小剂量组皮下注射0.2 mg/ml的卵清蛋白(ovalbumin,OVA)生理盐水溶液0.05 ml,大剂量组皮下注射20 mg/ml的OVA生理盐水溶液0.05 ml,阴性对照组和阳性对照组皮下注射同等剂量生理盐水.待小鼠长至6周时,开始对小剂量组、大剂量组、阳性对照组以OVA生理盐水腹腔注射和滴鼻诱发AR,阴性对照组予同等剂量的生理盐水腹腔注射和滴鼻诱发AR.观察小鼠症状、鼻黏膜组织学改变、检测血清OVA-IgE水平以及脾细胞培养上清液中白细胞介素(interleukin,IL)4、IL-5和γ干扰素(interferon,IFN)水平的差异.结果 新生小鼠皮下注射大剂量变应原组后期所诱发的AR与阳性对照组相比,症状明显减轻,鼻黏膜变态反应性炎症明显减轻.大剂量组血清OVA-IgE、IL-4、IL-5水平((x)±s,以下同)分别为(265.11±26.29)、(446.39±72.83)、(171.24±15.66)pg/ml,分别低于阳性对照组的(665.85±43.15)、(1113.45±30.47)、(255.36±30.96)pg/ml,差异有统计学意义(t值分别为0.000、0.000、0.009,P值均<0.05),而IFN-γ水平为(319.74±56.30)pg/ml,显著高于阳性对照组的(170.02±14.50)pg/ml,差异有统计学意义(t=0.000,P<0.05);而皮下注射小剂量变应原组的各指标改变与阳性对照组比较差异无统计学意义.结论 新生小鼠早期大剂量OVA皮下注射可对其后期由同种变应原所诱发的AR产生保护作用.
目的 探討新生小鼠早期變應原免疫對後期變應性鼻炎(allergic:rhinitis,AR)髮生髮展的影響.方法 BALB/c新生小鼠24隻,按隨機數字錶法分為4組:小劑量組、大劑量組、陰性對照組、暘性對照組,每組6隻.于齣生後第1、5、12天小劑量組皮下註射0.2 mg/ml的卵清蛋白(ovalbumin,OVA)生理鹽水溶液0.05 ml,大劑量組皮下註射20 mg/ml的OVA生理鹽水溶液0.05 ml,陰性對照組和暘性對照組皮下註射同等劑量生理鹽水.待小鼠長至6週時,開始對小劑量組、大劑量組、暘性對照組以OVA生理鹽水腹腔註射和滴鼻誘髮AR,陰性對照組予同等劑量的生理鹽水腹腔註射和滴鼻誘髮AR.觀察小鼠癥狀、鼻黏膜組織學改變、檢測血清OVA-IgE水平以及脾細胞培養上清液中白細胞介素(interleukin,IL)4、IL-5和γ榦擾素(interferon,IFN)水平的差異.結果 新生小鼠皮下註射大劑量變應原組後期所誘髮的AR與暘性對照組相比,癥狀明顯減輕,鼻黏膜變態反應性炎癥明顯減輕.大劑量組血清OVA-IgE、IL-4、IL-5水平((x)±s,以下同)分彆為(265.11±26.29)、(446.39±72.83)、(171.24±15.66)pg/ml,分彆低于暘性對照組的(665.85±43.15)、(1113.45±30.47)、(255.36±30.96)pg/ml,差異有統計學意義(t值分彆為0.000、0.000、0.009,P值均<0.05),而IFN-γ水平為(319.74±56.30)pg/ml,顯著高于暘性對照組的(170.02±14.50)pg/ml,差異有統計學意義(t=0.000,P<0.05);而皮下註射小劑量變應原組的各指標改變與暘性對照組比較差異無統計學意義.結論 新生小鼠早期大劑量OVA皮下註射可對其後期由同種變應原所誘髮的AR產生保護作用.
목적 탐토신생소서조기변응원면역대후기변응성비염(allergic:rhinitis,AR)발생발전적영향.방법 BALB/c신생소서24지,안수궤수자표법분위4조:소제량조、대제량조、음성대조조、양성대조조,매조6지.우출생후제1、5、12천소제량조피하주사0.2 mg/ml적란청단백(ovalbumin,OVA)생리염수용액0.05 ml,대제량조피하주사20 mg/ml적OVA생리염수용액0.05 ml,음성대조조화양성대조조피하주사동등제량생리염수.대소서장지6주시,개시대소제량조、대제량조、양성대조조이OVA생리염수복강주사화적비유발AR,음성대조조여동등제량적생리염수복강주사화적비유발AR.관찰소서증상、비점막조직학개변、검측혈청OVA-IgE수평이급비세포배양상청액중백세포개소(interleukin,IL)4、IL-5화γ간우소(interferon,IFN)수평적차이.결과 신생소서피하주사대제량변응원조후기소유발적AR여양성대조조상비,증상명현감경,비점막변태반응성염증명현감경.대제량조혈청OVA-IgE、IL-4、IL-5수평((x)±s,이하동)분별위(265.11±26.29)、(446.39±72.83)、(171.24±15.66)pg/ml,분별저우양성대조조적(665.85±43.15)、(1113.45±30.47)、(255.36±30.96)pg/ml,차이유통계학의의(t치분별위0.000、0.000、0.009,P치균<0.05),이IFN-γ수평위(319.74±56.30)pg/ml,현저고우양성대조조적(170.02±14.50)pg/ml,차이유통계학의의(t=0.000,P<0.05);이피하주사소제량변응원조적각지표개변여양성대조조비교차이무통계학의의.결론 신생소서조기대제량OVA피하주사가대기후기유동충변응원소유발적AR산생보호작용.
Objective To investigate the effect of early allergen exposure on later development of allergic rhinitis in mouse. Methods Twenty-four BALB/c neonates were randomly divided into 4 groups (low-dose group, high-dose group, negative control group and positive control group), each group had 6 mice. The mice were administered ovalbumin (OVA) by subcutaneous injection on day 1,5, 12 after birth (10 μg OVA in 0.05 ml saline for low-dose group, 1000 μg OVA in 0.05 ml saline for high-dose group,only saline for negative and positive control group).Then the mice were sensitized and intranasally challenged with OVA(saline without OVA was used in negative control group) after 6 weeks. Symptoms,histopathological changes of nasal mucosa were observed, OVA-IgE in serum was examined, cytokines IL-4,IL-5 and IFN-γ were detected in the supernatant of cultured splenic mononuclear cells. Results Compared to the positive control group, symptoms and nasal mucosa histological changes of high-dose group was indistinctive. The level of OVA-IgE and cytokines IL-4, IL-5 ((x)±s) in high-dose group [(265.11±26.29), (446.39±72.83) and (171.24±15.66) pg/ml, respectively] were significantly lower than those in positive control group [(665.85±43.15), (1113.45±30.47), (255.36±30.96) pg/ml,respectively, t value were 0.000, 0.000 and 0.009, respectively, all P<0.05]. The level of IFN-γ in high-dose group [(319.74±56.30) pg/ml] was significantly higher than those in positive control group [(170.02±14.50) pg/ml, t=0.000, P<0.05]. There was no significant difference of the results between the low-dose group and positive control group. Conclusions Neonatal immunization with high-dose OVA inhibited the future allergic rhinitis symptoms, nasal histological changes, serum OVA-IgE levels and Th1/Th2 cytokine imbalance, resulting in the protective effect.
